Shenzhen Zhongjia Biomedical Technology Co., Ltd. Shenzhen Zhongjia Biomedical Technology Co., Ltd.

Industry News

Industry News

Alzheimer's Treatment Advances: From Amyloid to Tau Multi-Target Research

2026-9-28

Alzheimer’s Treatment Continues to Advance: Research Expands from Amyloid to Tau and Multi-Target Strategies

  Alzheimer’s disease treatment is entering a more diverse stage of research and development.

  For many years, Alzheimer’s therapies mainly focused on managing symptoms related to memory, cognition, and behavior.

  In recent years, however, deeper understanding of the biological mechanisms behind the disease has led to the development of disease-modifying therapies that directly target Alzheimer’s pathology.

  At the same time, researchers are exploring additional treatment pathways beyond amyloid.

Anti-Amyloid Treatment Continues to Evolve

  Beta-amyloid accumulation is one of the major pathological features associated with Alzheimer’s disease.

  Several therapies targeting beta-amyloid are now being used in selected patients with early Alzheimer’s disease.

  In July 2026, the U.S. FDA approved a subcutaneous starter regimen for Leqembi, also known as lecanemab.

  According to the Alzheimer’s Association, eligible patients with mild cognitive impairment or early-stage Alzheimer’s may now have treatment options involving either intravenous infusion or subcutaneous administration, depending on the treatment plan.

  More flexible administration methods may help reduce some of the inconvenience associated with repeated visits to infusion centers.

  However, these therapies are not suitable for every person with Alzheimer’s disease.

  Patients generally need professional evaluation to confirm their disease stage and the presence of relevant Alzheimer’s pathology.

  Potential side effects and treatment risks must also be carefully assessed.

Researchers Are Paying Greater Attention to Tau Protein

  In addition to beta-amyloid, abnormal accumulation of tau protein is another key pathological feature of Alzheimer’s disease.

  In 2026, results were released from the Phase 2 CELIA clinical trial evaluating the tau-targeting therapy diranersen, also known as BIIB080.

  The treatment was shown to reduce abnormal tau levels in the brains of some patients and demonstrated signals that may suggest slower disease progression.

  However, the study did not meet its primary clinical endpoint.

  Therefore, diranersen cannot currently be regarded as a proven Alzheimer’s treatment.

  Despite this limitation, the study remains important because most approved disease-modifying therapies currently focus on beta-amyloid.

  Tau-targeted therapies represent another potential treatment pathway that may become increasingly important in the future.

Could Alzheimer’s Enter a Multi-Target Treatment Era?

  A growing number of researchers believe that Alzheimer’s disease is a complex condition involving multiple biological mechanisms rather than a single cause.

  Future treatment strategies may therefore involve several therapeutic targets, including:

  beta-amyloid removal, tau regulation, neuroinflammation, vascular health, metabolic function, and neuronal protection.

  This development may follow a pattern similar to cancer and cardiovascular disease, where treatment has gradually shifted from a single approach toward combinations tailored to different patient characteristics.

Earlier Diagnosis May Create More Treatment Options

  It is important to note that some current disease-modifying therapies are primarily intended for people in the early stages of Alzheimer’s disease.

  Therefore, persistent symptoms such as worsening recent memory, repeated questioning, getting lost in familiar places, or difficulty managing bills and everyday tasks should not automatically be dismissed as normal aging.

  Cognitive assessment, brain imaging, and appropriate biomarker testing can help doctors investigate the underlying cause.

  Although Alzheimer’s disease still cannot be completely cured, the field has progressed rapidly in recent years.

  From blood-based diagnostics and anti-amyloid therapies to tau-targeted research, new approaches are expanding the possibilities for earlier diagnosis and more individualized treatment.

  For patients and families, timely evaluation, accurate diagnosis, and discussion with qualified medical professionals remain essential parts of effective disease management.


Noticias relacionadas

  • Atención a la MLD: ¿por qué debería detectarse antes esta rara leucodistrofia?

    2026-10-23

  • ¿Se puede reducir el riesgo de Alzheimer? La OMS señala los riesgos de demencia modificables

    2026-9-28

  • La terapia del Alzheimer avanza: del amiloide a tau y a las estrategias multidiana

    2026-9-28

  • Nuevos avances en el cribado del Alzheimer: el análisis de sangre pasa a ocupar el centro de la inve

    2026-9-28

  • ¡Gran noticia! Otro medio de Zhongjia obtiene el registro DMF de la FDA

    2026-7-23